NEWTOWN, Pa.--(BUSINESS WIRE)--Quinnova Pharmaceuticals, Inc. announced today the launch of Salvax (Hydrating Topical Foam) Rx for the treatment of hyperkeratotic conditions such as psoriasis, keratosis pilaris, and xerosis. Salvax (Hydrating Topical Foam) contains 6% salicylic acid, a potent keratolytic agent, formulated in a water-lipid based foam. The product utilizes Quinnova’s patented Proderm TechnologyTM, containing a unique combination of physiological lipids, dimethicone, and glycerin which together help to restore the skin barrier, hydrate, and protect the skin, in addition to having anti-inflammatory properties.
